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 There exist published literature for cardiovascular disease 
(CVD) risk monitoring in cancer survivors but the extent 
of monitoring in clinical oncology practice is unknown. We 
performed an interactive survey at a Royal College of Physi-
cians conference (11 November 2016) attended by practitio-
ners with an interest in late effects of cancer treatment and 
supplemented the survey with an audit among 32 lung cancer 
survivors treated at St Peter’s NHS Hospital in 2012–2016. 
Among the practitioners, 40% reported CVD risk monitoring 
performed at least annually, which is compatible with Euro-
pean Group for Blood and Marrow Transplantation Guidelines, 
but 31% indicated that monitoring was never performed. In 
contrast, 77% felt that at least an annual assessment was 
required (p<0.001). Corroborating these data, among the lung 
cancer survivors, 31% and 16% had lipids or glucose/HbA1C 
measured annually, and 28% and 31% had never had these 
tests performed since their cancer treatment. Alerting health-
care providers to review protocols may help reduce CVD after 
cancer treatments. 
 KEYWORDS :  cardiometabolic risk ,  CVD prevention ,  health promo-
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 Introduction 
 In the UK, there are over two million cancer survivors 1 and 
this figure is set to rise to 5.3 million by 2040. 2 While prognosis 
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varies by cancer type, treatments have improved such that half 
of all people diagnosed with cancer in 2010–2011 in England 
and Wales are expected to survive for 10 years or longer, 
compared with a quarter of people diagnosed in 1971–1972. 3 
The role of GPs is becoming increasingly more important in 
cancer survivorship care since within an average GP population 
of 10,000 patients, there are about 275 cancer survivors of at 
least 5 years following diagnosis. 4 
 After progression or recurrence of cancer, cardiovascular 
disease (CVD) is the leading cause of death among survivors. 5 
Survivors from solid tumour cancers and haematological cancers 
both have a 1.6–1.7 times greater risk of CVD than non-cancer 
controls. 6 Many major cancers have the same long-term, 
cumulative, risk factors (eg smoking, obesity, physical inactivity, 
low consumption of fruit and vegetables). The stress of major 
illness, and its treatments, may aggravate CVD risk, and certain 
cancer treatments can present specific cardiovascular hazards, 
such as weight gain and metabolic disturbances. 
 The ‘late effect of cancer treatment’ is a phenomenon 
observed in cancer survivors whereby secondary health 
complications appear months to years after radiotherapy 7 and 
chemotherapy. 8 CVD emerges a few years post-treatment and 
the incidence is cumulative over subsequent years. 9,10 In parallel 
to CVD, metabolic disturbances – including obesity and 
central fat distribution indicated by large waist circumference, 
hypertension, dyslipidaemia and diabetes – which may be 
aggravated by cancer therapies, all also develop progressively 
post-treatment. 11–15 
 There are guidelines on monitoring CVD risk factors 
with the most recent recommendations for survivors of 
haematological cancer being the most comprehensive; 16 
previous recommendations have tended to be vague 17–19 or 
show little information on CVD risk monitoring. 20,21 Because 
of the complexity of late effects of cancer treatment, awareness 
of CVD risks among cancer survivors is low; little is known 
about the quality of risk monitoring and CVD-directed health 
promotion in cancer survivors in clinical practice. This is 
particularly true for the poor prognosis cancers whose small 
proportion of long-term survivors have largely been excluded 
from late effects studies. Therefore, we performed an interactive 
survey of healthcare providers to assess the frequency of CVD 
risk monitoring and discussion of CVD health promotion for 
cancer survivors. We supplemented this with a clinical audit 
of lung cancer survivors to assess the level of monitoring that 
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currently occurs following treatment of the poorer prognosis 
cancers. 
 Methods 
 Data procurement 
 An interactive survey was conducted at a Royal College of 
Physicians conference on 11 November 2016; a mixed group 
of 95 healthcare providers – including consultant physicians 
across different specialties, GPs, physician associates and nurses 
with a vested interest in late effects of cancer treatments – 
voted on ten questions: six related to the ‘frequency of 
cardiometabolic risk monitoring for their patients’, including 
weight, blood pressure (BP), waist circumference, lipids, 
glucose and smoking; three related to ‘how they feel about how 
often these risk factors should be monitored’; and one related 
to ‘how often they discuss CVD risk factors with their patients’. 
Complete questionnaires and data collected from interactive 
survey are shown in Table  1 . 
 The clinical patient audit was registered and approved by the 
Audit Department, Ashford and St Peter’s NHS Foundation 
Trust. Survivors of lung cancer were selected to represent a poor 
prognosis cancer and as a group known to have a high risk of 
cardiovascular late effects. 6 This audit identified 66 patients 
diagnosed with lung cancer by the hospital multidisciplinary 
team in 2012; 32 of these patients were still alive in 2016. Their 
frequency of monitoring and the levels of plasma lipids (total- 
and high-density lipoprotein (HDL) cholesterol) and glucose/
HbA1C (glycated haemoglobin) performed by primary and 
secondary care physicians during the 2012–2016 period were 
obtained retrospectively from central databases and cross-
checked by two doctors. 
 Statistical analysis 
 The interactive survey data were presented individually for 
each response to questions on CVD risk factors (weight, 
waist circumference, BP, lipids and glucose) followed by two 
composite variables; the first composite variable comprised 
the total number of responders to questions 1–5 (Table  1a ) on 
‘frequency of CVD risk monitoring for their patients’ (n=453) 
and the second to questions 7–10 (Table  1b ) on ‘how they feel 
about how often these risk factors should be monitored’ 
(n=256). Each frequency of monitoring category (ie ‘at least 
every 6 months’, ‘once a year’, ‘only occasionally’ or ‘never’) was 
expressed in proportions that were obtained from the number 
of responders to each frequency of monitoring category divided 
by the total number of responders (453 for the first and 256 for 
the second composite). 
 From the audit data, the mean values of lipids and glucose 
were calculated as the sum of each of these risk factors divided 
by the frequency they were measured. Descriptive analysis 
was performed to assess the frequency and proportions of risk 
monitoring and Chi-squared test to assess differences between 
categories where indicated using SPSS statistical package v22.0 
(SPSS Inc, Chicago, IL, USA). 
 Results 
 Interactive survey of healthcare providers 
 The questions asked in the survey and responses are 
documented in Table  1 . Of those surveyed, 1% of healthcare 
providers reported they monitor waist circumference ‘at least 
every 6 months’; 1% ‘at every clinic (at least once a year)’; 8% 
‘only occasionally’; and 89% reported they ‘never’ monitor 
waist circumference. These figures increased significantly 
(χ 2 =112, p<0.001) to 9.1%, 55.7%, 26.1% and 9.1%, 
respectively, when healthcare providers were asked ‘how often 
they feel waist circumference should be monitored’. Fig  1 
shows that the frequency of comprehensive monitoring for 
all CVD risk factors (composite variable comprising weight, 
waist circumference, BP, lipids and glucose) by healthcare 
providers ‘at least every 6 months’ was reported by 6% of 
survey respondents, ‘at every clinic (at least once a year)’ by 
34%, ‘only occasionally’ by 29% and ‘never’ by 31%. These 
figures were significantly different (χ 2 =120, p<0.001) to those 
seen when healthcare providers were asked how often they feel 
these risk factors should be monitored (17%, 60%, 20% and 
3%, respectively). 
 Results for other individual risk factors are shown in Table  1 . 
In addition to the specific monitoring, the survey also looked 
at how often potential health interventions might have been 
discussed with patients. It is notable that about 60% of 
 Table 1a.  Frequency of monitoring of cardiovascular risk factors for cancer survivors by healthcare providers 
 Response, n (%) 
 At least every 
6 months 
At every clinic visit 
(at least once a year) 
Only 
occasionally 
Never 
1 How often do you measure your patients’ weight? 7 (7.4) 60 (63.2) 24 (25.3) 4 (7.4)
2 How often do you measure your patients’ waist circumference? 1 (1.1) 1 (1.1) 7 (7.7) 81 (89.0)
3 How often do you measure your patients’ blood pressure? 11 (12.2) 42 (46.7) 24 (32.2) 8 (8.9)
4 How often do you measure your patients’ cholesterol? 1 (1.1) 28 (30.8) 25 (27.5) 37 (40.7)
5 How often do you measure your patients’ glucose? 8 (8.7) 24 (26.1) 46 (50.0) 14 (15.2)
6  When you see your patients, how often do you ask them about 
cigarette smoking?
7 (7.9) 45 (50.6) 27 (30.3) 10 (11.2)
7  When you see your patients, how often do you discuss 
cardiovascular risk factors?
3 (3.8) 27 (34.1) 35 (44.3) 14 (17.7)
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responders did get details of the patients’ smoking habit and 
40% routinely discuss CVD risk. 
 Clinical audit of CVD risk monitoring in cancer survivors 
 Of the 66 patients diagnosed with lung cancer in 2012, 
32 (48.5%) had survived to 2016 (4.7 years) and could be 
included in the study. The frequency of plasma lipid/glucose 
monitoring is documented in Table  2 . The median age of 
the patients at diagnosis was 71.2 years (interquartile range 
59.9–78.0). The mean (range) values for total cholesterol, HDL 
cholesterol and glucose were 4.45 mmol/L (3.80–5.29), 1.41 
mmol/L (1.15–1.73) and 5.95 mmol/L (4.97–6.73), respectively. 
There were 11 patients (34.4%) with dyslipidaemia (total 
cholesterol ≥5 mmol/L, HDL cholesterol <1.03 mmol/L for 
men, <1.29 mmol/L for women) and four patients (12.5%) with 
hyperglycaemia (fasting glucose levels ≥5.6 mmol/L). Overall, 
14 patients (43.8%) had at least one of these cardiometabolic 
risk factors. 
 Discussion 
 There exist a number of guidelines on monitoring CVD risk 
factors in cancer survivors with some appearing to be more 
comprehensive than others. 16–20 For example, the recent 
joint guidelines from the Center for International Blood and 
Marrow Transplant Research and European Society for Blood 
and Marrow Transplantation 16 recommend specific frequency 
of monitoring and treatment targets for individual CVD risk 
factors in cancer survivors following haematopoietic cell 
transplantation (HCT). These guidelines recommend screening 
at every clinic visit (at least once a year) for weight, body 
mass index (BMI) and BP, and yearly for waist circumference. 
Lipid measurement is recommended 3 months after allogenic 
HCT and should be repeated every 3–6 months for high-risk 
patients (treated with sirolimus, calcineurin inhibitors or 
corticosteroids) and every 5 years for standard-risk patients 
(males ≥35 years and females ≥45 years). Fasting blood glucose/
HbA1C should be checked 3 months after allogenic HCT and 
re-evaluated every 3–6 months for high-risk patients (treated 
with corticosteroids) and every 3 years for standard-risk 
patients. The Scottish Intercollegiate Guidelines Network 
guidelines 17 recommend annual assessment of BP and BMI, 
fasting glucose, insulin and lipids every 2 years in overweight/
obese individuals and every 5 years in non-overweight/ 
non-obese individuals. A report from the Cardiovascular 
Disease Task Force of the Children’s Oncology Group suggests 
monitoring fasting glucose and lipid profile every 3–5 years 
for survivors of childhood cancer. 18 Other guidelines on 
CVD risk monitoring of survivors of childhood malignancy 
recommend that, in additional to fasting glucose, lipids and 
HbA1C (although no specific frequency suggested), referral 
to endocrinologists should be considered for those with 
increased risk, eg bone marrow transplant recipients, especially 
total body irradiation or busulphan-based conditioning. 21 
While the precise monitoring frequency remains debatable 
and challenging, it is clear that monitoring, on the one hand 
should be tailored to the individual based on risk level (eg 
bone marrow transplant recipients, cranial radiotherapy, 
glucocorticoid treatment, growth hormone deficiency or 
high BMI/large waist circumference), and on the other 
hand should be recommended for all cancer survivors since 
 Table 1b.  How often healthcare providers think cardiovascular disease risk factors should be monitored in 
cancer survivors 
 Response, n (%) 
 At least every 
6 months 
At every clinic visit 
(at least once a year) 
Only 
occasionally 
Never 
8  How often do you feel your patients’ weight and blood pressure 
should be checked?
19 (22.4) 63 (74.1) 3 (3.5) 0 (0.0)
9  How often do you feel your patients’ waist circumference should 
be checked?
8 (9.1) 49 (55.7) 23 (26.1) 8 (9.1)
10  How often do you feel your patients’ cholesterol and blood 
glucose should be checked?
17 (20.5) 41 (49.4) 25 (30.1) 0 (0.0)
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 Fig 1.  Frequency of monitoring risk factors for cardiovascular disease 
(CVD) in cancer survivors. CVD risk factors include weight, waist circumfer-
ence, blood pressure, lipids and glucose. Differences between categories: 
χ 2 =112 (p<0.001). Please note, the composite variables in this ﬁ gure contain 
waist circumference as well as other factors; this results in a ‘dilutional effect’ 
and, therefore, the proportions of responders for each category of frequency 
of monitoring would differ between this ﬁ gure and the results in Table  1 . 
Please refer to the methods section for details on derivation of composite 
variables . 
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 Table 2.  Frequency of lipid and glucose/HbA1C 
monitoring in lung cancer survivors (n=32) 56 
months (4.7 years) after diagnosis 
 Frequency of monitoring 
 Three times Twice Once None 
Patients who had lipids 
monitored
31% 16% 25% 28%
Patients who had 
glucose/HbA1C 
monitored
16% 19% 34% 31%
 HbA1C = glycated haemaglobin 
survivors of solid tumours have been shown to have similar 
late cardiovascular effects to survivors of haematological 
malignancies. 6 
 The present study has demonstrated rather infrequent 
CVD risk monitoring of a group of lung cancer survivors in 
secondary care. Survivors of lung cancer have been shown to be 
among the highest risk groups for cardiovascular events 6 and 
improvements in cancer treatment will increase the numbers of 
individuals at risk. Results obtained from patients’ blood tests 
using electronic databases were consistent with the responses 
from healthcare providers in an interactive survey, and with 
results from a previous audit by Sekhar  et al 22 – about one-
third never had risk factors measured. This lack of CVD risk 
monitoring is concerning as cancer survivors are known to have 
a high risk of CVD and related death. There appears to be low 
awareness of the need for monitoring CVD risk factors. Urgent 
action is therefore necessary to promote awareness among 
healthcare providers of this, particularly for long-term cancer 
survivors because CVD tends to manifest many years later as a 
consequence of the late effects of cancer treatments. 
 The underlying reasons for the poor CVD monitoring in 
cancer survivors are uncertain and likely to be multifactorial. 
A lack of awareness among healthcare providers of the 
elevated risk and of current guidelines may play a part. Cancer 
specialists may have been more focused on the cancer itself and 
tended to accept the elevated CVD risk factors if CVD does 
not emerge until a number of years after cancer treatments. It 
is therefore imperative that oncologists take responsibility for 
raising awareness of the risks with the patient and the GP; the 
responsibility for screening of CVD risk then lies with the GP 
(through the implementation of the treatment record summary 
as a component of the recovery package). 23 Our survey indicates 
that healthcare providers actually wish to monitor CVD risk for 
their patients more frequently than their current practice, but 
we did not have information on the underlying reason for the 
lack of monitoring. Long-term follow-up of cancer survivors 
with diligent monitoring of general health – including CVD 
risk factors, particularly the reversible components of metabolic 
syndrome – is necessary in order to intervene effectively. 
Primary prevention has been advocated for cancer survivors. 9 
However, our interactive survey revealed that up to nine out of 
ten healthcare providers indicated that they never measured 
their patients’ waist circumference. In contrast, when asked 
how often waist circumference should be checked, almost two-
thirds of these specialists felt that it should be checked at least 
every 6–12 months. Given their high risk, CVD screening in 
cancer survivors should use metabolic syndrome criteria from 
the International Diabetes Federation 24 with lower cut-off levels 
of waist circumference and glucose than those defined by the 
National Cholesterol Education Program. 25 
 In our interactive survey, smoking habit and general CVD risk 
factors were only occasionally, or never, discussed by 40–60% 
of healthcare providers. This lack of health promotion has also 
been reported in a larger survey, revealing about one-third of 
cancer survivors did not have health promotion discussion with 
their healthcare providers. 26 
 Managing treatment consequences is a key goal of new cancer 
strategy and solutions to this given through the implementation 
of the recovery package. 23 Dissemination of information on 
CVD monitoring for cancer survivors across all healthcare 
disciplines is vital to ensure continuity of management of 
general health in the long term. The role of GPs is vital given 
increasing numbers of survivors are now being cared for in 
primary care. 4 However, it has recently been shown that half of 
the time CVD risk is incompletely monitored in primary care. 22 
 The strengths of this study include data sources from patients’ 
investigations as well as direct survey of healthcare providers, 
which show concordant results consistent with previous studies. 
The present study is limited because of its small sample size 
and the healthcare providers surveyed were not from within 
the specialty of oncology. However, as previously discussed, the 
long-term follow-up of cancer survivors is usually performed 
by non-oncology specialists such as GPs and nurses. We did not 
have the opportunity to include physical activity, dietary habits, 
including alcohol intake, and adherence to treatment – which 
may provide important insights into the aetiology of CVD 
in cancer survivors. We did not have data about treatment of 
cardiovascular risk factors. We are not aware of any studies on 
detection of risk factors that automatically lead to treatment in 
cancer survivors but believe that any risk identified in cancer 
survivors should be managed at least as aggressively as that 
in non-cancer population. A large national survey is being 
planned to extend our findings, by including survivors of 
prostate, teratoma, breast and haematology-oncology cancers, 
and adult survivors of childhood cancers. 
 Conclusions 
 Despite their now well-established increased risk of CVD 
and related death, current monitoring of correctable CVD 
risk factors in cancer survivors by healthcare providers 
is infrequent, and does not meet recommendations from 
published literature. Regular monitoring and early management 
of CVD risk factors is required, and should be incorporated into 
guidelines, to prevent the elevated rates of CVD after cancer 
treatment, and thereby improve cancer survivorship. ■ 
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